Published in Vaccine Weekly, August 31st, 2005
Total revenues for the quarter ended June 30, 2005, were $1 million compared to $5.5 million for the same period in 2004. Revenues in the second quarter of 2005 reflect a decrease in collaboration revenue following the March 2005 ending of the allergy collaboration between Dynavax and UCB Farchim (UCB) and the return to Dynavax of full rights to its allergy program.
Revenues in the second-quarter 2005 were driven by grants awarded by the U.S. National Institute of Allergy and Infectious Diseases and by the Alliance for Lupus Research. For the 6 months ended June...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly